Patents by Inventor Cecile GOUTTEFANGES

Cecile GOUTTEFANGES has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Powerful MHC-class II peptides derived from survivin
    Patent number: 9498512
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: November 22, 2016
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Cecile Gouttefanges, Toni Weinschenk, Peter Lewandrowski
  • NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN
    Publication number: 20140127242
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: June 19, 2012
    Publication date: May 8, 2014
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Cécile GOUTTEFANGES, Toni WEINSCHENK, Peter LEWANDROWSKI
  • Powerful MHC-class II peptides derived from survivin
    Patent number: 8647629
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: February 11, 2014
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Cécile Gouttefanges, Toni Weinschenk, Peter Lewandrowski
  • NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN
    Publication number: 20130323272
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: June 28, 2013
    Publication date: December 5, 2013
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefanges, Toni Weinschenk, Peter Lewandrowski
  • NOVEL AND POWERFUL MHC-CLASS II PEPTIDES DERIVED FROM SURVIVIN
    Publication number: 20100029571
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 4, 2010
    Applicant: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Cecile GOUTTEFANGES, Toni WEINSCHENK, Peter LEWANDROWSKI